MDGL

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in West Conshohocken, Pennsylvania, focused on developing innovative therapies for cardiovascular, metabolic, and liver diseases. Its lead product candidate, resmetirom, is aimed at treating non-alcoholic steatohepatitis (NASH), addressing a significant unmet medical need in an underserved patient population. With a robust pipeline and promising clinical trial results, Madrigal is positioned as a key player in the metabolic disease sector, presenting a compelling investment opportunity for institutional investors seeking to support advancements in health solutions.